The Clinical Value of MRI Testing in Prostate Cancer

Article

In Partnership With:

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.

Vickers says that, as of now, the most valuable clinical benefit of MRI is to find the cancers that TRUS biopsies miss. More of these clinically significant cancers are found with MRI, though the long-term effects of these cancers are still largely unkown.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD